Therapeutic potential of TNFα inhibitors in chronic inflammatory disorders: Past and future

Area of Science:

• Immunology
• Pharmacology
• Biochemistry

Background:

• Biological TNFα inhibitors have significantly improved treatment for immune-mediated inflammatory diseases over the past two decades.
• Five anti-TNFα biologics are currently approved, with biosimilars forthcoming, expanding patient options and knowledge of TNFα biology.
• Despite advances, unmet needs persist, including side effects, reduced tolerance, and therapeutic resistance associated with current anti-TNFα biologics.

Purpose of the Study:

• To highlight the significant impact of biological TNFα inhibitors on immune diseases.
• To underscore the remaining challenges and unmet needs in TNFα-targeted therapies.
• To advocate for the development of novel TNFα inhibitors, particularly TNFR1-specific small molecules for oral administration.

Main Methods:

• Review of existing literature on TNFα inhibitors and their clinical applications.
• Analysis of the benefits and limitations of current biological anti-TNFα therapies.
• Identification of key areas for future drug development in TNFα inhibition.

Main Results:

• TNFα inhibitors have revolutionized the management of rheumatoid arthritis, Crohn's disease, and other immune disorders.
• Existing therapies face challenges related to adverse effects, patient tolerance, and resistance, limiting their long-term efficacy.
• The potential efficacy of anti-TNFα therapies in early-stage osteoarthritis and spinal pain warrants further investigation.

Conclusions:

• While biological TNFα inhibitors represent a major therapeutic advance, significant unmet needs remain.
• There is a critical need for the development of next-generation TNFα inhibitors.
• Future research should focus on TNFR1-specific inhibitors, ideally orally available small molecules, to overcome current treatment limitations.